Now live: Pro — the full 13F research suite for serious investorsSee pricing →
FCPM III SERVICES B.V.

Q4 2024 · 13F-HR

FCPM III SERVICES B.V.holdings as filed

Filed 2025-02-14 · accession 0000950123-25-002356

$592.4M
Reported value
8
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$272.3M46.0%10,597,181CommonSHARED
26818M108DYNDYNE THERAPEUTICS INC$128.7M21.7%5,462,846CommonSHARED
29286M105ENGENE HOLDINGS INC$64.1M10.8%9,632,561CommonSHARED
088786108BCYCBICYCLE THERAPEUTICS PLC$48.3M8.16%3,452,330CommonSHARED
76029N106REPLREPLIMUNE GROUP INC$48.1M8.12%3,970,668CommonSHARED
04635X102CATBUSDASTRIA THERAPEUTICS INC$25.7M4.34%2,872,537CommonSHARED
00449L102698ACHILLES THERAPEUTICS PLC$2.7M0.46%2,390,050CommonSHARED
29286M113ENGENE HOLDINGS INC$2.4M0.41%2,878,148CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.